Pfizer and BioNTech said Thursday that they are considering adding a third dose to the vaccine regime and testing a new version of the coronavirus in South African variants.
As countries around the world rush to vaccinate people, more contagious variants, such as those first detected in South Africa and those first detected in the United Kingdom, are more resistant to existing vaccines. There is growing concern.
In one study, US and German drug companies said they would look at what would happen when a third dose of a double-dose vaccine was given 6-12 months after booster immunization.
They said they were also in talks with regulators to test a modified version of the original vaccine to address a South African variant known as B.1.351, in a statement.
In a statement, Pfizer CEO Dr. Albert Bourla said, “We have taken decisive action and taken several steps to prepare for resistance to vaccine protection. There are. “
South African variants are considered one of the more dangerous of the current mutations because they evade some of the blocking effects of antibodies that target older coronavirus strains.
This means that people infected with the classic strain are more susceptible to reinfection, and studies have also shown that the mutants have partially reduced the protection of current-generation vaccines.
Moderna, another company whose vaccine has been approved for emergency use in the United States, sent a dose of a new Covid-19 vaccine candidate for coronavirus variants in South Africa to the National Institutes of Health for testing on Wednesday. Said it was shipped.
Pfizer To Test Third Dose, Tweaked Vaccine To Target S.African Strain Source link Pfizer To Test Third Dose, Tweaked Vaccine To Target S.African Strain